FAQ

Remitogen

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2001-2001
0120012001

Related topics

Related topics

1 relation

Broader (1)

apolizumab

Related mentions per year

Related mentions per year

2001-2009
200020022004200620082010
Remitogen
apolizumab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2002
2002
In vivo pharmacodynamic effects of Hu1D10 (remitogen), a humanized antibody reactive against a polymorphic determinant of HLA-DR expressed on B cells.
The humanized monoclonal antibody Hu1D10 (Remitogen, Protein Design Labs, Fremont, CA) recognizes a polymorphic determinant of… (More)
Is this relevant?
2002
2002
Enhanced killing of B lymphoma cells by granulocyte colony-stimulating factor-primed effector cells and Hu1D10--a humanized human leucocyte antigen DR antibody.
Antibody-based approaches have become a novel treatment modality for lymphoma patients. Humanized 1D10 (Hu1D10; Remitogen) is… (More)
Is this relevant?
2002
2002
Host genetics and HIV—removing the mask
 
  • figure 1
Is this relevant?
2002
2002
Protein design labs begins Phase I trial of Remitogen in cancer patients with solid tumors.
  • Expert review of anticancer therapy
  • 2002
 
Is this relevant?
2001
2001
Phase II trial of Remitogen (humanized 1D10) monoclonal antibody targeting class II in patients with relapsed low-grade or follicular lymphoma.
 
Is this relevant?